Welcome to today's Medical News Today News Alert containing today's medical news headlines for your chosen categories. You will only receive these alerts when new news is available for your chosen categories.
To unsubscribe from our news alerts, or to alter any of your subscription details (name,e-mail address etc) please see
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
----------------------------------------------
** BREAST CANCER News **
Lymphedema Risk For Breast Cancer Survivors Increased By Obesity
http://www.medicalnewstoday.com/articles/133691.php
Throughout the world, 10 million breast cancer survivors have a lifetime risk for developing lymphedema, a chronic condition that involves swelling of the limbs and impacts physical and psychosocial health.
----------------------------------------------
** CANCER / ONCOLOGY News **
Removal Of Pelvic Lymph Nodes Or Radiotherapy Cannot Be Recommended As Routine Treatments In Women With Early Endometrial Cancer (ASTEC Study)
http://www.medicalnewstoday.com/articles/134035.php
Two Articles published Online first and in an upcoming edition of <i>The Lancet</i> show that two common adjuvant treatments for women with early endometrial cancer - removing the pelvic lymph nodes or external beam radiotherapy - should not be part of routine care.
NCCN Provides Oncology Training For Nearly 200 Medical Professionals In Philadelphia
http://www.medicalnewstoday.com/articles/133700.php
With the recent news that cancer is expected to be the world's new leading cause of death by 2010, it is crucial that individuals who help manage patients with cancer are educated on the latest advances in oncology care.
CHMP Recommends Granting Marketing Authorisation For FIRMAGON(R) (degarelix) For Treatment Of Prostate Cancer
http://www.medicalnewstoday.com/articles/133655.php
Ferring Pharmaceuticals received notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer.
Breakthrough In Cancer Therapy Using Radiation - Linac-MR System Operational With MR Imaging During 6 MV Irradiation
http://www.medicalnewstoday.com/articles/133652.php
Fallone from the Cross Cancer Institute (CCI) , Alberta Cancer Board of the Alberta Health Services (Edmonton, AB) reports that CCI medical physicists have produced the first image from a linac-MR hybrid system on December 10, 2008.
Hotel, Restaurant And Carpentry Trades Are Among Professions Posing Highest Risks For Cancer Of The Oesophagus
http://www.medicalnewstoday.com/articles/133644.php
A new study led by Spanish researchers has revealed that exposure to certain substances may increase the risk of cancer of the oesophagus. The hotel and restaurant trades, animal handling, mining and carpentry are some of the professions posing the highest risk.
Dangerous Skin Cancer
http://www.medicalnewstoday.com/articles/133640.php
The German Cancer Society has worked out new guidelines for the diagnosis and treatment of malignant melanoma a disease with unfavorable prognosis. Malignant melanoma is responsible for 90% of deaths from skin cancer.
A Cellular Task Force To Safeguard Genome Stability
http://www.medicalnewstoday.com/articles/133639.php
The maintenance of genome stability is crucial for protecting an organism against the onset of cancer and the study of the mechanisms controlling genome stability represents one of the most promising frontiers in cancer research.
Scientists Study How Asbestos Fibers Trigger Cancer In Human Cells
http://www.medicalnewstoday.com/articles/133636.php
Ohio State University scientists believe they are the first in the world to study the molecular underpinnings of cancer by probing individual bonds between an asbestos fiber and human cells. Though any clinical application is years away, the researchers hope their findings could aid in drug development efforts targeting illnesses caused by excessive exposure to asbestos, including the deadly cancer called mesothelioma.
PTC Therapeutics Initiates Two Clinical Trials Of PTC299 In Cancer Patients
http://www.medicalnewstoday.com/articles/133628.php
PTC Therapeutics, Inc. (PTC) announced the initiation of two clinical trials of the company's product candidate PTC299 in adult patients with solid tumor cancers and Kaposi Sarcoma, a HIV-related cancer.
Lance Armstrong Foundation Awards Nearly $2 Million With 11 Grants To Leading Research Institutions In The U.S. And Australia
http://www.medicalnewstoday.com/articles/133617.php
Recently the Lance ArmstrongFoundation (LAF) awarded nearly $2 million with 11 grants to leadingresearch institutions in the U.S. and Australia. The 2008 researchgrantees represent City of Hope (Duarte, CA); University ofCalifornia at Los Angeles (Los Angeles, CA); University ofConnecticut (Storrs, CT); Georgetown University (Washington, DC);Veterans Affairs Medical Center (VAMC) and Indiana University(Indianapolis, IN); Montana State University (Bozeman, MT);Massachusetts General Hospital (Boston, MA); Columbia University (NewYork, NY); Ohio State University (Columbus, OH); and the University ofSydney (Sydney, Australia).
Institute Of Cancer Research Named UK's Top Research Centre
http://www.medicalnewstoday.com/articles/133615.php
The Institute of Cancer Research has been ranked as the UK's leading academic research centre by the Times Higher Education, today. The coveted independent ranking of the UK's 132 educational research centres was based on the Higher Education Funding Council's Research Assessment Exercise.
----------------------------------------------
** CERVICAL CANCER / HPV VACCINE News **
High HPV Vaccination Coverage Already Achieved In England
http://www.medicalnewstoday.com/articles/133998.php
More than 70 per cent of 12-13 year old girls have already had their first HPV (human papillomavirus) jab since the vaccination campaign started in September, Public Health Minister Dawn Primarolo announced today.
Swedish Officials Investigate Ties Between AstraZeneca, Nobel Foundation Over Award For Discovery Of HPV
http://www.medicalnewstoday.com/articles/133985.php
Swedish officials are investigating whether the pharmaceutical company <A href="http://www.astrazeneca.com/" target=_new>AstraZeneca</A> could have improperly influenced this year's Nobel Prize for medicine, which was <A href="News2?news_iv_ctrl=-1&abbr=daily2_&page=NewsArticle&id=13724" target=_new>awarded</A> to the researcher who discovered the human papillomavirus, London's <A href="http://www.
----------------------------------------------
** COLORECTAL CANCER News **
Maslinic Acid, Isolated From Olive Pomace, Provides A Natural Defence Against Colon Cancer
http://www.medicalnewstoday.com/articles/133641.php
Researchers from the University of Granada and the University of Barcelona have shown that treatment with maslinic acid, a triterpenoid compound isolated from olive-skin pomace, results in a significant inhibition of cell proliferation and causes apoptotic death in colon-cancer cells.
----------------------------------------------
** LUNG CANCER News **
American Lung Association Offers Seven Tips To Quit Smoking This New Year
http://www.medicalnewstoday.com/articles/133630.php
Many people will make New Year's resolutions to quit smoking this year. With the economy in turmoil, quitting smoking is not only good for your health, but also your wallet. Having a solid smoking cessation plan can greatly improve one's chance for success.
----------------------------------------------
** LYMPHOMA / LEUKEMIA News **
No news for this category today.
----------------------------------------------
** PROSTATE / PROSTATE CANCER News **
CHMP Recommends Granting Marketing Authorisation For FIRMAGON(R) (degarelix) For Treatment Of Prostate Cancer
http://www.medicalnewstoday.com/articles/133655.php
Ferring Pharmaceuticals received notification that the Committee for Medicinal Products for Human Use (CHMP), part of the European Medicines Agency (EMEA), has adopted a positive opinion and is recommending to grant a marketing authorization for FIRMAGON(R) (degarelix), a new GnRH receptor antagonist indicated for patients with advanced, hormone-dependent prostate cancer.
-------------------------------------------------------------
You are receiving this news alert e-mail because you subscribed via an online form on our web site. If you wish to unsubscribe, please visit
http://www.medicalnewstoday.com/newsalerts.php?changemydetails=y .
No comments:
Post a Comment